Inhibitors of phosphodiesterase as cancer therapeutics
- PMID: 29574203
- DOI: 10.1016/j.ejmech.2018.03.046
Inhibitors of phosphodiesterase as cancer therapeutics
Abstract
Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in many physiological processes including visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function. PDEs are composed of 11 different families and each family contains different subtypes. The distribution, expression, regulation mode and sensitivity to inhibitors of each subtype are different, and they are involved in cancer, inflammation, asthma, depression, erectile dysfunction and other pathological processes of development. A large number of studies have shown that PDEs play an important role in the development of tumors by affecting the intracellular level of cAMP and/or cGMP and PDEs could become diagnostic markers or therapeutic targets. This review will give a brief overview of the expression and regulation of PDE families in the process of tumorigenesis and their anti-tumor inhibitors, which may guide the design of novel therapeutic drugs targeting PDEs for anticancer agent.
Keywords: Cancer; Phosphodiesterase; Phosphodiesterase inhibitors; cAMP; cGMP.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Targeting cancer with phosphodiesterase inhibitors.Expert Opin Investig Drugs. 2010 Jan;19(1):117-31. doi: 10.1517/13543780903485642. Expert Opin Investig Drugs. 2010. PMID: 20001559 Review.
-
Structure-Based Discovery of PDEs Inhibitors.Curr Top Med Chem. 2016;16(9):917-33. doi: 10.2174/1568026615666150825142134. Curr Top Med Chem. 2016. PMID: 26303429 Review.
-
Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.Exp Biol Med (Maywood). 2007 Jan;232(1):38-51. Exp Biol Med (Maywood). 2007. PMID: 17202584 Review.
-
The role of phosphodiesterases in schizophrenia : therapeutic implications.CNS Drugs. 2008;22(12):983-93. doi: 10.2165/0023210-200822120-00002. CNS Drugs. 2008. PMID: 18998737 Review.
-
Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors.Life Sci. 2019 Aug 1;230:150-161. doi: 10.1016/j.lfs.2019.05.043. Epub 2019 May 21. Life Sci. 2019. PMID: 31125564 Review.
Cited by
-
Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.J Cell Mol Med. 2024 May;28(10):e18395. doi: 10.1111/jcmm.18395. J Cell Mol Med. 2024. PMID: 38774995 Free PMC article.
-
Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma.Sci Rep. 2024 Mar 21;14(1):6813. doi: 10.1038/s41598-024-57533-w. Sci Rep. 2024. PMID: 38514754 Free PMC article.
-
Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer.Cell Death Discov. 2024 Mar 9;10(1):124. doi: 10.1038/s41420-024-01890-y. Cell Death Discov. 2024. PMID: 38461159 Free PMC article.
-
Antihypertensive drug targets and breast cancer risk: a two-sample Mendelian randomization study.Eur J Epidemiol. 2024 May;39(5):535-548. doi: 10.1007/s10654-024-01103-x. Epub 2024 Feb 24. Eur J Epidemiol. 2024. PMID: 38396187 Free PMC article.
-
Co-treatment of Naringenin and Ketoprofen-RGD Suppresses Cell Proliferation via Calmodulin/PDE/cAMP/PKA Axis Pathway in Leukemia and Ovarian Cancer Cells.Iran J Pharm Res. 2023 Jun 19;22(1):e136131. doi: 10.5812/ijpr-136131. eCollection 2023 Jan-Dec. Iran J Pharm Res. 2023. PMID: 38116560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
